Nuvectis Pharma, Inc.
NVCT
$6.49
-$0.38-5.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.98M | 1.89M | 1.95M | 1.54M | 1.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.60M | 5.57M | 6.45M | 4.36M | 4.64M |
| Operating Income | -6.60M | -5.57M | -6.45M | -4.36M | -4.64M |
| Income Before Tax | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M |
| EBIT | -6.60M | -5.57M | -6.45M | -4.36M | -4.64M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.30 | -0.27 | -0.35 | -0.24 | -0.26 |
| Normalized Basic EPS | -0.19 | -0.17 | -0.22 | -0.15 | -0.16 |
| EPS Diluted | -0.30 | -0.27 | -0.35 | -0.24 | -0.26 |
| Normalized Diluted EPS | -0.19 | -0.17 | -0.22 | -0.15 | -0.16 |
| Average Basic Shares Outstanding | 21.37M | 19.94M | 17.76M | 17.23M | 16.90M |
| Average Diluted Shares Outstanding | 21.37M | 19.94M | 17.76M | 17.23M | 16.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |